Atreca, a biopharmaceutical company in the clinical stage of development, focuses on the discovery and creation of antibody-based immunotherapeutics to treat numerous kinds of solid tumor types. The company's chief product candidate, ATRC-101, is a monoclonal antibody that utilizes an innovative mechanism of action and a target derived from an antibody identified through Atreca's proprietary discovery platform. ATRC-101 has in vitro reactions with the majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. Atreca is also developing two additional products, including APN-122597, which is a receptor tyrosine kinase targeting tumor tissues, and ATRC-501/MAM01, targeting the circumsporozoite protein of Plasmodium falciparum for malaria treatment. Atreca has established its name in the industry through collaboration and license agreements. The company has a particular collaboration and license agreement with Xencor to conduct research, development, and commercialization on CD3 bispecific antibodies in oncology. The company also secured a licensing agreement with the Bill & Melinda Gates Medical Research Institute to work on the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Founded in 2010 and headquartered in San Carlos, California, Atreca is a prominent biopharmaceutical player, attracting industry-wide attention for its innovative research in clinical-stage treatments for solid tumor types.